(Arginine + sodium succinate) is under clinical development by Polysan and currently in Phase II for Atherosclerosis. According to GlobalData, Phase II drugs for Atherosclerosis have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Arginine + sodium succinate)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Arginine + sodium succinate) overview
Unifuzol is under development for the treatment of obliterating atherosclerosis of the vessels of the lower extremities. The drug candidate is a fixed dose combination of arginine and sodium succinate. It is formulated as solution for infusion and is administered by intravenous route. The drug candidate was also under development for peripheral vascular disease.
Polysan overview
Polysan is a manufacturer of medicinal products or preparations for the treatment of geriatrics disorders, oncology indications, viral and bacterial infections. Polysan is headquartered in Saint-Petersburg, Russia.
For a complete picture of (Arginine + sodium succinate)’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
